...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Antibiotics: An International Journal >Functional molecules from natural sources: organized by the Royal Society of Chemistry Biotechnology Group, Magdalen College, Oxford, UK, 6-8 July 2009.
【24h】

Functional molecules from natural sources: organized by the Royal Society of Chemistry Biotechnology Group, Magdalen College, Oxford, UK, 6-8 July 2009.

机译：天然来源的功能分子：由英国牛津玛格达琳学院皇家化学生物技术学会组织，2009年7月6日至8日。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Naturally occurring compounds have been, and continue to be, a major source of both new leads and commercially successful products for various industrial sectors, notably pharmaceuticals, agrochemicals and animal health. The last decade has, however, seen many challenges to, and changes in, the industrial use of natural products for new lead finding. Many large company natural product discovery groups are no longer operating, following trends toward discovery based on more 'convenient' synthetic chemical diversity such as combinatorial chemistry. At the same time, a number of small companies dedicated to natural product discovery and development have been founded, with varying degrees of success. Recent years have also been successful in terms of the approval of new classes of natural product-derived drugs, notable examples being the lipopeptide antibacterial agent daptomy-cin (Cubicin),1 the first pleuromutilin derivative for human use, Retapamulin,2 the rapamycin-derived anticancer agents Temsirolimus3 and Everolimus,4 and the anticancer epothilone derivative Ixabepi-lone.5 This conference followed two earlier meetings organized by the RSC Biotechnology Group6,7 and aimed to highlight current trends, challenges and successes in the exploitation of natural products.
机译：天然存在的化合物一直是并将继续成为各种工业领域的新线索和商业上成功的产品的主要来源，特别是制药，农用化学品和动物保健。然而，在过去的十年中，天然产物在工业上用于新的发现线索的过程面临着许多挑战和变化。许多大型公司的天然产物发现小组已经不再运作，这是基于基于更“方便”的合成化学多样性（例如组合化学）的发现趋势。同时，已经建立了许多致力于天然产物发现和开发的小型公司，并取得了不同程度的成功。近年来，在新型天然产物药物的批准方面也取得了成功，值得注意的例子是脂肽抗菌剂达托霉素（Cubicin）1，第一种人类使用的截短侧耳素衍生物瑞塔帕林（Retapamulin）2，雷帕霉素。衍生的抗癌药Temsirolimus3和Everolimus [4]，以及抗癌埃博霉素衍生物Ixabepi-lone [5]。本次会议是继RSC生物技术集团6,7组织的两次较早的会议之后的，目的是强调天然产物开发的当前趋势，挑战和成功。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号